CVS Health (CVS) closed the most recent trading day at $61.96, moving -2.12% from the previous trading session. This change lagged the S&P 500's 0.01% loss on the day. Elsewhere, the Dow lost 0.32%, ...

The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it ...

The most recent trading session ended with CVS Health (CVS) standing at $54.55, reflecting a +1.36% shift from the previouse trading day's closing. The stock's performance was ahead of the S&P 500 ...

That shows the power of CVS’ market saturation; it pushed Hyrimoz through every arm of its business. CVS said the list price of Hyrimoz is 81% cheaper than brand-name Humira.

Barclays upgraded CVS Health Inc (NYSE:CVS) on higher Pharmacy & Consumer Wellness (PCW) estimates as headwinds are offset by share gains, with further upside potential from CostVantage. Despite ...

--CVS Health ® today released the Rx Report: Transforming Community Pharmacy to Make Healthier Happen Together, which explores the ongoing evolution of community pharmacy as well as opportunities ...

For 2025, Barclays estimates market forecasts include expectations of 110 basis points in Medicare margin expansion, which is on the lower end of CVS’s target range of 100-200 bps.